Gopisankar Mohanannair Geethadevi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gopisankar Mohanannair Geethadevi has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Johnson George
Centre for Medicine Use and Safety Faculty of Pharmacy and Pharmaceutical Sciences Monash University Parkville Victoria Australia
3 shared publications - Patrick Kwan
Department of Neuroscience, School of Translational Medicine Monash University Melbourne Victoria Australia
3 shared publications - Zanfina Ademi
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
3 shared publications - Zhibin Chen
Department of Neuroscience, School of Translational Medicine Monash University Melbourne Victoria Australia
3 shared publications - Amanda J. Cross
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
2 shared publications Catherine Ferreira
2 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1718-1728
A randomized controlled trial of a multimodality digital health intervention to aid the delivery of the modified ketogenic diet therapy for epilepsy: The Keto eCoach trial protocol
Objective: Dietary therapy is an effective treatment for drug‐resistant epilepsy; however, low adherence presents a significant barrier to use in the clinical setting. This study aims to evaluate a multimodality digital health intervention to overcome this barrier and improve outcomes in adults undertaking the modified ketogenic diet for epilepsy. Method: This is a two‐arm, randomized, controlled trial. A total of 136 participants will be randomized 1:1 to receive the modified ketogenic diet as per standard clinical care, or with the addition of the multimodality digital health intervention for 12 weeks. The intervention will include three components: (1) digital diaries, (2) a novel, at‐home, saliva‐based ketone testing device, and (3) dynamic dietitian support. Results: The primary treatment benefit will be determined using the epilepsy desirability of outcome rank, a composite outcome measure co‐designed with people living with drug‐resistant epilepsy. Secondary outcomes will include seizure frequency, treatment retention, adverse events, psychiatric symptoms, quality of life, medication use, cost effectiveness, and acceptability of the intervention. Significance: The results of this trial will provide evidence on the effectiveness of using this innovative digital health intervention approach to improve treatment outcomes of dietary therapy for drug‐resistant epilepsy. Ethics and Dissemination: This study has received approval from the Alfred Hospital Human Research Ethics Committee (Reference No.: 723/23). The results will be disseminated via peer‐reviewed publications and publicly available plain language summaries. Trial Registration Number: Australian New Zealand Clinical Trials Registry (ANZCTR, ACTRN12624000486527). Plain Language Summary: This trial aims to find out if a 12‐week digital health program can improve treatment outcomes of people living with epilepsy. We will invite 136 people commencing on the modified ketogenic diet to be randomly assigned to the digital health program or standard clinic care. The treatment outcome will be assessed combining seizure frequency, side effects, and quality of life.
- 7 September 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1718-1728
Open AccessA randomized controlled trial of a multimodality digital health intervention to aid the delivery of the modified ketogenic diet therapy for epilepsy: The Keto eCoach trial protocol
Objective: Dietary therapy is an effective treatment for drug‐resistant epilepsy; however, low adherence presents a significant barrier to use in the clinical setting. This study aims to evaluate a multimodality digital health intervention to overcome this barrier and improve outcomes in adults undertaking the modified ketogenic diet for epilepsy. Method: This is a two‐arm, randomized, controlled trial. A total of 136 participants will be randomized 1:1 to receive the modified ketogenic diet as per standard clinical care, or with the addition of the multimodality digital health intervention for 12 weeks. The intervention will include three components: (1) digital diaries, (2) a novel, at‐home, saliva‐based ketone testing device, and (3) dynamic dietitian support. Results: The primary treatment benefit will be determined using the epilepsy desirability of outcome rank, a composite outcome measure co‐designed with people living with drug‐resistant epilepsy. Secondary outcomes will include seizure frequency, treatment retention, adverse events, psychiatric symptoms, quality of life, medication use, cost effectiveness, and acceptability of the intervention. Significance: The results of this trial will provide evidence on the effectiveness of using this innovative digital health intervention approach to improve treatment outcomes of dietary therapy for drug‐resistant epilepsy. Ethics and Dissemination: This study has received approval from the Alfred Hospital Human Research Ethics Committee (Reference No.: 723/23). The results will be disseminated via peer‐reviewed publications and publicly available plain language summaries. Trial Registration Number: Australian New Zealand Clinical Trials Registry (ANZCTR, ACTRN12624000486527). Plain Language Summary: This trial aims to find out if a 12‐week digital health program can improve treatment outcomes of people living with epilepsy. We will invite 136 people commencing on the modified ketogenic diet to be randomly assigned to the digital health program or standard clinic care. The treatment outcome will be assessed combining seizure frequency, side effects, and quality of life.
- 9 September 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (5) , e214011
Impact of Epilepsy on Productivity and Quality of Life
Epilepsy occurs in 4% of Australians over their lifetime. European studies show that over 75% of epilepsy-related health care costs are indirect, with 80% due to absenteeism. In Australia, studies capturing absenteeism in epilepsy are limited and presenteeism data are unavailable. This study investigated employment rates, absenteeism, presenteeism, and quality of life reported by people who experienced seizures in Australia. The Australian Epilepsy Project (AEP) is a prospective cohort study of adults with first unprovoked seizure (FUS), newly diagnosed epilepsy (NDE), or focal drug-resistant epilepsy (DRE), referred mainly from tertiary care clinics. This study is a cross-sectional analysis of AEP baseline data, reporting quality of life (EuroQol 5 Dimensions [EQ-5D-5L] and Quality of Life in Epilepsy Inventory [QOLIE-31]); employment rates; and the prevalence and extent of absenteeism and presenteeism, assessed using the Work Productivity and Activity Impairment questionnaire. Correlations were assessed using either Spearman or Pearson methods. Logistic regression was used for odds. Of 670 participants (median age 35.6 years, interquartile range [IQR] 26.9-47.3 years, 53.4% female participants), 15.9% had FUS, 34.6% had NDE, and 49.4% had DRE. The median (IQR) EQ-5D-5L score for the cohort was 0.93 (0.83-0.96). The mean QOLIE-31 score was lower for people with DRE (49.7 ± 16.8), compared with both NDE (57.9 ± 17.4, p = 0.003) and FUS (59.4 ± 16.2, p = 0.003) groups. The employment rate was 62.3% (95% CI 58.4%-66.1%), with lower rates in the DRE group (53.9% p < 0.001). 30.8% (95% CI 26.1%-35.7%) of workers reported absenteeism, 45% (95% CI 40.0%-50.0%) reported presenteeism, and 23% (95% CI 19.6%-28.5%) reported both. Among those with absenteeism, each year, full-time workers lost a median of 60 (IQR 31.5-189.4) days of work and part-time workers lost 37.8 (IQR 18.9-75.7) days of work. The mean percentage of presenteeism was higher in patients with DRE compared with those with NDE (22.9% vs 15.2%, p = 0.007). People with absenteeism and presenteeism had lower QOLIE-31 scores (mean difference -9.9, 95% CI -6.4 to -13.3, p < 0.001; -9.2, 95% CI -0.016 to -0.076, p < 0.001) than those without. Employment and work productivity are commonly reduced in people who experience seizures, particularly those with DRE. Lower productivity was associated with poorer quality of life. Further studies are needed to understand the nature of this relationship.
- 9 September 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (5) , e214011
Impact of Epilepsy on Productivity and Quality of Life
Epilepsy occurs in 4% of Australians over their lifetime. European studies show that over 75% of epilepsy-related health care costs are indirect, with 80% due to absenteeism. In Australia, studies capturing absenteeism in epilepsy are limited and presenteeism data are unavailable. This study investigated employment rates, absenteeism, presenteeism, and quality of life reported by people who experienced seizures in Australia. The Australian Epilepsy Project (AEP) is a prospective cohort study of adults with first unprovoked seizure (FUS), newly diagnosed epilepsy (NDE), or focal drug-resistant epilepsy (DRE), referred mainly from tertiary care clinics. This study is a cross-sectional analysis of AEP baseline data, reporting quality of life (EuroQol 5 Dimensions [EQ-5D-5L] and Quality of Life in Epilepsy Inventory [QOLIE-31]); employment rates; and the prevalence and extent of absenteeism and presenteeism, assessed using the Work Productivity and Activity Impairment questionnaire. Correlations were assessed using either Spearman or Pearson methods. Logistic regression was used for odds. Of 670 participants (median age 35.6 years, interquartile range [IQR] 26.9-47.3 years, 53.4% female participants), 15.9% had FUS, 34.6% had NDE, and 49.4% had DRE. The median (IQR) EQ-5D-5L score for the cohort was 0.93 (0.83-0.96). The mean QOLIE-31 score was lower for people with DRE (49.7 ± 16.8), compared with both NDE (57.9 ± 17.4, p = 0.003) and FUS (59.4 ± 16.2, p = 0.003) groups. The employment rate was 62.3% (95% CI 58.4%-66.1%), with lower rates in the DRE group (53.9% p < 0.001). 30.8% (95% CI 26.1%-35.7%) of workers reported absenteeism, 45% (95% CI 40.0%-50.0%) reported presenteeism, and 23% (95% CI 19.6%-28.5%) reported both. Among those with absenteeism, each year, full-time workers lost a median of 60 (IQR 31.5-189.4) days of work and part-time workers lost 37.8 (IQR 18.9-75.7) days of work. The mean percentage of presenteeism was higher in patients with DRE compared with those with NDE (22.9% vs 15.2%, p = 0.007). People with absenteeism and presenteeism had lower QOLIE-31 scores (mean difference -9.9, 95% CI -6.4 to -13.3, p < 0.001; -9.2, 95% CI -0.016 to -0.076, p < 0.001) than those without. Employment and work productivity are commonly reduced in people who experience seizures, particularly those with DRE. Lower productivity was associated with poorer quality of life. Further studies are needed to understand the nature of this relationship.
- Open Access
Ten‐year projection of adult epilepsy burden in Australia
Objective: The World Health Organization's Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders calls for more epilepsy care centers, but a population‐level estimate of epilepsy's projected burden to justify this investment from a societal perspective is lacking. We aimed to project the burden of epilepsy using dynamic life table modeling including number of deaths, years of life, quality‐adjusted life years (QALYs), productivity‐adjusted life years (PALYs), health care costs, and number of people to be screened for surgical eligibility in the Australian adult population (aged 18–80 years) from 2024 to 2033.Methods: A dynamic model was developed to capture incident and prevalent epilepsy in Australia, using five health states: not seizure‐free non‐drug resistant (NSF‐NDRE), seizure‐free non‐drug resistant (SF‐NDRE), not seizure‐free drug resistant (NSF‐DRE), seizure‐free drug‐resistant (SF‐DRE), and death in 1‐year cycles. The inputs came from published studies, Glosgow cohort study and from the Australian Epilepsy Project.Results: In 10 years, 82 723 Australian adults had incident epilepsy, whereas 125 223 formed the prevalent cohort. Over 10 years, the epilepsy population experienced 15 227 deaths and accrued 1 209 280 years of life, distributed as 23.6% NSF‐NDRE, 58.3% SF‐NDRE, 15.8% NSF‐DRE, and 2.1% SF‐DRE. The population accrued 992 812 QALYs and 442 600 PALYs. Total health care costs reached $14.2 billion US dollars (USD), of which NSF‐DRE contributed 35%. Uncontrolled seizures resulted in the loss of 84 881 QALYs, 19 333 PALYs, $4.5 billion USD, and 4603 lives. A total of 10 665 individuals were eligible for surgical evaluation, with an additional 383 projected annually through 2033.Significance: This dynamic life table model, based on the current standard of care for epilepsy, demonstrates quality of life impact, productivity loss, and cost burden due to uncontrolled seizures and drug resistance, supporting the need for further investment in epilepsy care. This approach can be applied to other countries to inform policy decisions in epilepsy from a societal perspective.
Open AccessTen‐year projection of adult epilepsy burden in Australia
Objective: The World Health Organization's Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders calls for more epilepsy care centers, but a population‐level estimate of epilepsy's projected burden to justify this investment from a societal perspective is lacking. We aimed to project the burden of epilepsy using dynamic life table modeling including number of deaths, years of life, quality‐adjusted life years (QALYs), productivity‐adjusted life years (PALYs), health care costs, and number of people to be screened for surgical eligibility in the Australian adult population (aged 18–80 years) from 2024 to 2033.Methods: A dynamic model was developed to capture incident and prevalent epilepsy in Australia, using five health states: not seizure‐free non‐drug resistant (NSF‐NDRE), seizure‐free non‐drug resistant (SF‐NDRE), not seizure‐free drug resistant (NSF‐DRE), seizure‐free drug‐resistant (SF‐DRE), and death in 1‐year cycles. The inputs came from published studies, Glosgow cohort study and from the Australian Epilepsy Project.Results: In 10 years, 82 723 Australian adults had incident epilepsy, whereas 125 223 formed the prevalent cohort. Over 10 years, the epilepsy population experienced 15 227 deaths and accrued 1 209 280 years of life, distributed as 23.6% NSF‐NDRE, 58.3% SF‐NDRE, 15.8% NSF‐DRE, and 2.1% SF‐DRE. The population accrued 992 812 QALYs and 442 600 PALYs. Total health care costs reached $14.2 billion US dollars (USD), of which NSF‐DRE contributed 35%. Uncontrolled seizures resulted in the loss of 84 881 QALYs, 19 333 PALYs, $4.5 billion USD, and 4603 lives. A total of 10 665 individuals were eligible for surgical evaluation, with an additional 383 projected annually through 2033.Significance: This dynamic life table model, based on the current standard of care for epilepsy, demonstrates quality of life impact, productivity loss, and cost burden due to uncontrolled seizures and drug resistance, supporting the need for further investment in epilepsy care. This approach can be applied to other countries to inform policy decisions in epilepsy from a societal perspective.
- Open Access
A novel, multidomain, primary care nurse-led and mHealth-assisted intervention for dementia risk reduction in middle-aged adults (HAPPI MIND): study protocol for a cluster randomised controlled trial
Introduction Middle-aged multidomain risk reduction interventions targeting modifiable risk factors for dementia may delay or prevent a third of dementia cases in later life. We describe the protocol of a cluster randomised controlled trial (cRCT), HAPPI MIND (Holistic Approach in Primary care for PreventIng Memory Impairment aNd Dementia). HAPPI MIND will evaluate the efficacy of a multidomain, nurse-led, mHealth supported intervention for assessing dementia risk and reducing associated risk factors in middle-aged adults in the Australian primary care setting. Methods and analysis General practice clinics (n≥26) across Victoria and New South Wales, Australia, will be recruited and randomised. Practice nurses will be trained to implement the HAPPI MIND intervention or a brief intervention. Patients of participating practices aged 45–65 years with ≥2 potential dementia risk factors will be identified and recruited (approximately 15 patients/clinic). Brief intervention participants receive a personalised report outlining their risk factors for dementia based on Australian National University Alzheimer’s Disease Risk Index (ANU-ADRI) scores, education booklet and referral to their general practitioner as appropriate. HAPPI MIND participants receive the brief intervention as well as six individualised dementia risk reduction sessions with a nurse trained in motivational interviewing and principles of behaviour change, a personalised risk reduction action plan and access to the purpose-built HAPPI MIND smartphone app for risk factor self-management. Follow-up data collection will occur at 12, 24 and 36 months. Primary outcome is ANU-ADRI score change at 12 months from baseline. Secondary outcomes include change in cognition, quality of life and individual risk factors of dementia. Ethics and dissemination Project approved by Monash University Human Research Ethics Committee (ID: 28273). Results will be disseminated in peer-reviewed journals and at healthcare conferences. If effective in reducing dementia risk, the HAPPI MIND intervention could be integrated into primary care, scaled up nationally and sustained over time. Trial registration number ACTRN12621001168842.
Open AccessA novel, multidomain, primary care nurse-led and mHealth-assisted intervention for dementia risk reduction in middle-aged adults (HAPPI MIND): study protocol for a cluster randomised controlled trial
Introduction Middle-aged multidomain risk reduction interventions targeting modifiable risk factors for dementia may delay or prevent a third of dementia cases in later life. We describe the protocol of a cluster randomised controlled trial (cRCT), HAPPI MIND (Holistic Approach in Primary care for PreventIng Memory Impairment aNd Dementia). HAPPI MIND will evaluate the efficacy of a multidomain, nurse-led, mHealth supported intervention for assessing dementia risk and reducing associated risk factors in middle-aged adults in the Australian primary care setting. Methods and analysis General practice clinics (n≥26) across Victoria and New South Wales, Australia, will be recruited and randomised. Practice nurses will be trained to implement the HAPPI MIND intervention or a brief intervention. Patients of participating practices aged 45–65 years with ≥2 potential dementia risk factors will be identified and recruited (approximately 15 patients/clinic). Brief intervention participants receive a personalised report outlining their risk factors for dementia based on Australian National University Alzheimer’s Disease Risk Index (ANU-ADRI) scores, education booklet and referral to their general practitioner as appropriate. HAPPI MIND participants receive the brief intervention as well as six individualised dementia risk reduction sessions with a nurse trained in motivational interviewing and principles of behaviour change, a personalised risk reduction action plan and access to the purpose-built HAPPI MIND smartphone app for risk factor self-management. Follow-up data collection will occur at 12, 24 and 36 months. Primary outcome is ANU-ADRI score change at 12 months from baseline. Secondary outcomes include change in cognition, quality of life and individual risk factors of dementia. Ethics and dissemination Project approved by Monash University Human Research Ethics Committee (ID: 28273). Results will be disseminated in peer-reviewed journals and at healthcare conferences. If effective in reducing dementia risk, the HAPPI MIND intervention could be integrated into primary care, scaled up nationally and sustained over time. Trial registration number ACTRN12621001168842.
- Open Access
- 5 December 2022
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 51 (12)
Validity of three risk prediction models for dementia or cognitive impairment in Australia
Background: no studies have compared the predictive validity of different dementia risk prediction models in Australia. Objectives: (i) to investigate the predictive validity of the Australian National University-Alzheimer’s Disease Risk Index (ANU-ADRI), LIfestyle for BRAin Health (LIBRA) Index and cardiovascular risk factors, ageing and dementia study (CAIDE) models for predicting probable dementia/cognitive impairment in an Australian cohort. (ii) To develop and assess the predictive validity of a new hybrid model combining variables from the three models. Methods: the Hunter Community Study (HCS) included 3,306 adults aged 55–85 years with a median follow-up of 7.1 years. Probable dementia/cognitive impairment was defined using Admitted Patient Data Collection, dispensing of cholinesterase inhibitors or memantine, or a cognitive test. Model validity was assessed by calibration and discrimination. A hybrid model was developed using deep neural network analysis, a machine learning method. Results: 120 (3.6%) participants developed probable dementia/cognitive impairment. Mean calibration by ANU-ADRI, LIBRA, CAIDE and the hybrid model was 19, 0.5, 4.7 and 3.4%, respectively. The discrimination of the models was 0.65 (95% CI 0.60–0.70), 0.65 (95% CI 0.60–0.71), 0.54 (95% CI 0.49–0.58) and 0.80 (95% CI 0.78–0.83), respectively. Conclusion: ANU-ADRI and LIBRA were better dementia prediction tools than CAIDE for identification of high-risk individuals in this cohort. ANU-ADRI overestimated and LIBRA underestimated the risk. The new hybrid model had a higher predictive performance than the other models but it needs to be validated independently in longitudinal studies.
- 5 December 2022
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 51 (12)
Open AccessValidity of three risk prediction models for dementia or cognitive impairment in Australia
Background: no studies have compared the predictive validity of different dementia risk prediction models in Australia. Objectives: (i) to investigate the predictive validity of the Australian National University-Alzheimer’s Disease Risk Index (ANU-ADRI), LIfestyle for BRAin Health (LIBRA) Index and cardiovascular risk factors, ageing and dementia study (CAIDE) models for predicting probable dementia/cognitive impairment in an Australian cohort. (ii) To develop and assess the predictive validity of a new hybrid model combining variables from the three models. Methods: the Hunter Community Study (HCS) included 3,306 adults aged 55–85 years with a median follow-up of 7.1 years. Probable dementia/cognitive impairment was defined using Admitted Patient Data Collection, dispensing of cholinesterase inhibitors or memantine, or a cognitive test. Model validity was assessed by calibration and discrimination. A hybrid model was developed using deep neural network analysis, a machine learning method. Results: 120 (3.6%) participants developed probable dementia/cognitive impairment. Mean calibration by ANU-ADRI, LIBRA, CAIDE and the hybrid model was 19, 0.5, 4.7 and 3.4%, respectively. The discrimination of the models was 0.65 (95% CI 0.60–0.70), 0.65 (95% CI 0.60–0.71), 0.54 (95% CI 0.49–0.58) and 0.80 (95% CI 0.78–0.83), respectively. Conclusion: ANU-ADRI and LIBRA were better dementia prediction tools than CAIDE for identification of high-risk individuals in this cohort. ANU-ADRI overestimated and LIBRA underestimated the risk. The new hybrid model had a higher predictive performance than the other models but it needs to be validated independently in longitudinal studies.
- Open Access
- 19 July 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (10) , 2428-2435
Cancer chemotherapy drug wastage in a tertiary care hospital in India—A 3‐month prospective and 1‐year retrospective study
This study prospectively quantified wastage of cancer chemotherapeutic drugs in an oncology unit to find the associated cost in 3 months. Retrospective analysis of drug usage for 12 months was also conducted to determine the expected drug loss in 1 year. The effect of vial sharing was evaluated under the assumption of sharing. A significant drug wastage of 19.72% (95% confidence interval [CI], 14.52–24.93%) in 3 months and 17.14% (95% CI 14.69–19.59%) in 1 year occurred in our oncology unit. Number of vials purchased (r = 0.362, p < 0.01), weight (r = −0.146, P < .01) and body surface area (r = −0.26, P < .01) correlated with the drug wasted. Vial sharing assumption showed a 9% (95% CI, 2.5–15.5%) reduction in cost in 1 year.
- 19 July 2019
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (10) , 2428-2435
Open AccessCancer chemotherapy drug wastage in a tertiary care hospital in India—A 3‐month prospective and 1‐year retrospective study
This study prospectively quantified wastage of cancer chemotherapeutic drugs in an oncology unit to find the associated cost in 3 months. Retrospective analysis of drug usage for 12 months was also conducted to determine the expected drug loss in 1 year. The effect of vial sharing was evaluated under the assumption of sharing. A significant drug wastage of 19.72% (95% confidence interval [CI], 14.52–24.93%) in 3 months and 17.14% (95% CI 14.69–19.59%) in 1 year occurred in our oncology unit. Number of vials purchased (r = 0.362, p < 0.01), weight (r = −0.146, P < .01) and body surface area (r = −0.26, P < .01) correlated with the drug wasted. Vial sharing assumption showed a 9% (95% CI, 2.5–15.5%) reduction in cost in 1 year.
- Open Access
- 24 September 2018
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 7 (10) , 1877-1881
An assessment of knowledge, attitude and practices (KAP) towards warfarin medication among patients with prosthetic valve in a tertiary care hospital of south India
Background: Warfarin is a drug with narrow therapeutic index. It requires varied adequate doses for achieving target INR so as to prevent episodes of thromboembolism. It is important to properly educate the patient while prescribing this drug to reduce the side effects and maintain perfect anticoagulation status. This study was done to assess the baseline Knowledge, Attitude and Practices (KAP) towards warfarin medication among patients with cardiac valve replacement in a tertiary care hospital of south India to get a baseline data which can recommend implementation of health education programs targeting these patients.Methods: An observational cross-sectional study was approved by Institute Ethics Committee JIPMER, Puducherry. It included patients on treatment with warfarin maintenance therapy for a period of not less than three months following cardiac valve replacement in the months of October 2016 to October 2017. The questionnaire included 39 questions of qualitative and quantitative basis, which was scored for a total of 50 and analysed using SPSS software.Results: About 240 patients were interviewed who attended cardiothoracic vascular surgery outpatient department and taking warfarin for at least 3 months following surgery of valve replacement. Patients were divided into two groups. Group A included patients who achieved target INR and group B are those out of target INR. 15.7 percent (35) had low score, 76.2 (160) had medium score and 15 (7.1) percent had high scores in group A. In group B 22(81.5%) had medium score and 5 (18.5%) had high score. The median score was more among patients with higher education (p=0.01). There was no significant difference between scores between different age groups or profession.Conclusions: Lack of adequate knowledge exists in patients who are followed in CTVS OPD when assessed about the basic nature of their disease and drug use. It has been shown that group B had more score which may be due to more education they may have received owing to non-attainment of target INR. This study acts as a baseline and thus advocates the need of proper patient education for patients taking warfarin which may improve the treatment outcome.
- 24 September 2018
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 7 (10) , 1877-1881
Open AccessAn assessment of knowledge, attitude and practices (KAP) towards warfarin medication among patients with prosthetic valve in a tertiary care hospital of south India
Background: Warfarin is a drug with narrow therapeutic index. It requires varied adequate doses for achieving target INR so as to prevent episodes of thromboembolism. It is important to properly educate the patient while prescribing this drug to reduce the side effects and maintain perfect anticoagulation status. This study was done to assess the baseline Knowledge, Attitude and Practices (KAP) towards warfarin medication among patients with cardiac valve replacement in a tertiary care hospital of south India to get a baseline data which can recommend implementation of health education programs targeting these patients.Methods: An observational cross-sectional study was approved by Institute Ethics Committee JIPMER, Puducherry. It included patients on treatment with warfarin maintenance therapy for a period of not less than three months following cardiac valve replacement in the months of October 2016 to October 2017. The questionnaire included 39 questions of qualitative and quantitative basis, which was scored for a total of 50 and analysed using SPSS software.Results: About 240 patients were interviewed who attended cardiothoracic vascular surgery outpatient department and taking warfarin for at least 3 months following surgery of valve replacement. Patients were divided into two groups. Group A included patients who achieved target INR and group B are those out of target INR. 15.7 percent (35) had low score, 76.2 (160) had medium score and 15 (7.1) percent had high scores in group A. In group B 22(81.5%) had medium score and 5 (18.5%) had high score. The median score was more among patients with higher education (p=0.01). There was no significant difference between scores between different age groups or profession.Conclusions: Lack of adequate knowledge exists in patients who are followed in CTVS OPD when assessed about the basic nature of their disease and drug use. It has been shown that group B had more score which may be due to more education they may have received owing to non-attainment of target INR. This study acts as a baseline and thus advocates the need of proper patient education for patients taking warfarin which may improve the treatment outcome.